# A Study of the Pharmacokinetics, Safety and Tolerability of Single Doses of VR647 Inhalation Suspension Administered Using the VR647 Inhalation System in Children With Wheezing, Reactive Airway Disease or Mild Asthma

> **NCT03421730** · PHASE1 · COMPLETED · sponsor: **Vectura Limited** · enrollment: 17 (actual)

## Conditions studied

- Wheezing
- Reactive Airway Disease
- Mild Asthma

## Interventions

- **COMBINATION_PRODUCT:** VR647 Inhalation Suspension (budesonide) 1 mg/2 mL delivered by the VR647 Inhalation System
- **COMBINATION_PRODUCT:** 1 mg/2 mL Pulmicort Respules delivered by a conventional jet nebulizer

## Key facts

- **NCT ID:** NCT03421730
- **Lead sponsor:** Vectura Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-12-18
- **Primary completion:** 2018-03-21
- **Final completion:** 2018-03-27
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2019-10-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03421730

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03421730, "A Study of the Pharmacokinetics, Safety and Tolerability of Single Doses of VR647 Inhalation Suspension Administered Using the VR647 Inhalation System in Children With Wheezing, Reactive Airway Disease or Mild Asthma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03421730. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*